CAPRICOR THERAPEUTICS INC

NASDAQ: CAPR (Capricor Therapeutics, Inc.)

Last update: 07 Sep, 2:35AM

6.74

0.80 (13.47%)

Previous Close 5.94
Open 6.00
Volume 2,149,815
Avg. Volume (3M) 2,482,956
Market Cap 308,132,576
Price / Sales 19.97
Price / Book 2.76
52 Weeks Range
4.05 (-39%) — 23.40 (247%)
Earnings Date 11 Aug 2025
Operating Margin (TTM) -329.90%
Diluted EPS (TTM) -1.37
Quarterly Revenue Growth (YOY) -7.90%
Total Debt/Equity (MRQ) 0.98%
Current Ratio (MRQ) 6.55
Operating Cash Flow (TTM) -45.16 M
Levered Free Cash Flow (TTM) -28.17 M
Return on Assets (TTM) -35.24%
Return on Equity (TTM) -75.39%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Capricor Therapeutics, Inc. Bearish Bearish

AIStockmoo Score

1.5
Analyst Consensus 1.0
Insider Activity NA
Price Volatility 4.5
Technical Moving Averages 1.0
Technical Oscillators -0.5
Average 1.50

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CAPR 308 M - - 2.76
EXEL 11 B - 18.82 5.07
HALO 9 B - 17.60 26.64
BPMC 8 B - - 24.41
NUVL 6 B - - 6.21
TGTX 5 B - 84.63 18.63

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Sector Healthcare
Industry Biotechnology
Investment Style Small Growth
% Held by Insiders 16.80%
% Held by Institutions 41.06%

Ownership

Name Date Shares Held
Black Diamond Financial, Llc 30 Jun 2025 277,737
52 Weeks Range
4.05 (-39%) — 23.40 (247%)
Price Target Range
12.00 (78%) — 29.00 (330%)
High 29.00 (Jones Trading, 330.27%) Buy
Median 22.00 (226.41%)
Low 12.00 (Roth Capital, 78.04%) Buy
Average 21.60 (220.48%)
Total 5 Buy
Avg. Price @ Call 8.35
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 11 Sep 2025 24.00 (256.08%) Buy 6.44
11 Jul 2025 24.00 (256.08%) Buy 7.64
Roth Capital 14 Jul 2025 12.00 (78.04%) Buy 7.39
17 Jun 2025 31.00 (359.94%) Buy 12.19
B. Riley Securities 26 Jun 2025 21.00 (211.57%) Buy 10.18
Jones Trading 25 Jun 2025 29.00 (330.27%) Buy 10.05
Oppenheimer 23 Jun 2025 22.00 (226.41%) Buy 7.68

No data within this time range.

Date Type Details
09 Sep 2025 Announcement Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
09 Sep 2025 Announcement Tune Into the SueWallSt Podcast: Capricor Therapeutics, Inc. (CAPR) Lawsuit Explained
05 Sep 2025 Announcement Latest SueWallSt Podcast: What CAPR Investors Need to Know About the Lawsuit
04 Sep 2025 Announcement SueWallSt Podcast Series Launches With Focus on Capricor Therapeutics, Inc. (CAPR) Fraud Allegations
02 Sep 2025 Announcement Shareholders SueWallSt in New Class Action Against Capricor Therapeutics, Inc. - Act Now
21 Aug 2025 Announcement Investors SueWallSt as Capricor Therapeutics, Inc. Faces Securities Fraud Allegations
18 Aug 2025 Announcement Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
11 Aug 2025 Announcement Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08 Aug 2025 Announcement Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
06 Aug 2025 Announcement Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
28 Jul 2025 Announcement Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
11 Jul 2025 Announcement Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
24 Jun 2025 Announcement Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
20 Jun 2025 Announcement Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
17 Jun 2025 Announcement Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria